Circulating tumour DNA abundance and potential utility in de novo metastatic prostate cancer
Several systemic therapeutic options exist for metastatic castration sensitive prostate cancer (mCSPC). Circulating tumour DNA can profile metastatic castration resistant prostate cancer and influence treatment decisions, but remains untested in mCSPC. We set out to determine ctDNA abundance at de novo mCSPC diagnosis and whether ctDNA provides complementary clinically relevant information to a prostate biopsy. We collected and sequenced 77 plasma cell-free DNA samples from 53 newly diagnosed patients with mCSPC. Targeted sequencing was also performed on DNA from 48 diagnostic prostate tissue samples.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
|Illumina HiSeq 2500
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Eur Urol 75: 2019 667-675
Integrating chromatin accessibility states in the design of targeted sequencing panels for liquid biopsy.
Sci Rep 12: 2022 10447